ClinicalTrials.gg
RecruitingNCT06226324Updated Jan 26, 2024

fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus

An observational study in Systemic Lupus Erythematosus, sponsored by The Affiliated Hospital of Inner Mongolia Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by The Affiliated Hospital of Inner Mongolia Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
15th of 21
120 · median 180
Started
2023
with 23 others
Observational
21 of 266
15 open now
Primary completion
2024-06
later than 2 of 190 live
Registered
107th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 15th largest by planned enrollment of the 21 observational ones that give a count, is one of 24 that started in 2023, is one of 21 observational ones, reaches primary completion later than 2 of the 190 other live ones, and was the 107th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs and systems. The central nervous system is one of the most commonly involved parts, and the involvement of the nervous system is called neuropsychiatric lupus, which is one of the most common complications of SLE and the main cause of death. Cognitive impairment and emotional disorders are the most common neuropsychiatric symptoms, with a prevalence of up to 80%. Studies have shown that the prevalence of NPSLE is between 37% and 95%. Compared with SLE patients, the mortality rate increases by three times. Early diagnosis and treatment play an important role in improving the quality of life of patients. fMRI has the advantages of non-invasive, in vivo and high repeatability, and can detect the brain function changes of patients early before the structural changes. This study uses fMR to compare the differences in brain function changes between SLE patients and healthy controls, explore the neuroimaging mechanism of brain injury, and provide reference for the early clinical intervene.

Read the detailed description

The fMRI images of 40 SLE patients with neuropsychiatric symptoms, 40 SLE patients without neuropsychiatric symptoms and 40 healthy controls matched by sex, age and education level were collected. fMRI was selected as an evaluation method to compare the differences in brain functional changes among the three groups, and to explore the specific brain regions in the imaging of early brain injury in SLE. Neurocognitive assessment was performed on all subjects, clinical data and laboratory serum markers of SLE patients were collected, and the correlation between SLE patients and specific brain regions was analyzed, and multiple regression models were constructed to provide imaging references for early clinical diagnosis and intervention in the process of NPSLE.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

There were 80 SLE patients (40 with and without neuropsychiatric symptoms) and 40 healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and gender matched the case group
  2. Right-handed
  3. No cerebrovascular, neurological or mental diseases
  4. Can cooperate with MRI and neuropsychiatric examination

Exclusion criteria

Exclusion Criteria:

  1. Patients with serious diseases of other systems
  2. Patients with diseases of central nervous system
  3. Other rheumatic immune system diseases
  4. Neuropsychiatric history
  5. Smokers, drug users or alcoholics
  6. MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • SLE with neuropsychiatric symptoms

    1. Neuropsychiatric symptoms meeting the 1999 ACR definition 2. Ages 18-55y 3. Female 4. Right-handed 5. Can cooperate with MRI and neuropsychiatric examination

    Other: neuropsychological test

  • SLE without neuropsychiatric symptoms

    1. Patients who meet the 2019 ACR diagnostic criteria for SLE 2. Patients without neuropsychiatric symptoms 3. Age 18-55y 4. Female 5. Right-handed 6. Able to cooperate with MRI and neuropsychiatric examination

    Other: neuropsychological test

  • Healthy control group

    1. Age and gender matched the case group 2. Right-handed 3. No cerebrovascular, neurological or mental diseases 4. Can cooperate with MRI and neuropsychiatric examination

    Other: neuropsychological test

Interventions

  • Otherneuropsychological test

    The subjects were evaluated for memory, cognition, mood and sleep

06

What researchers measure

Primary outcomes

  1. fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus

    Early identification of specific brain areas of brain injury in lupus patients by fMRI provides objective imaging markers for early clinical intervention.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2024, 17 months after the start.

Of 90 non-industry observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 212. This study's planned 17 months is below that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 26, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06226324
Lead sponsor
The Affiliated Hospital of Inner Mongolia Medical University
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Jan 1, 2023
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 26, 2024

Study contacts

Peng fei Qiao
Contact
24853170@qq.com
15904718239
Peng fei Qiao
study director · Affiliated Hospital of Inner Mongolia Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion